Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Sales 246

Sales Vaccination Vaccine Medicine 246

Bio Pharma Dive

APRIL 23, 2024

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

Sales 169

Sales Drugs 169

Pharmaceutical Technology

MAY 1, 2024

Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and angiopoietin-2 inhibitor for wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), and macular oedema following retinal vein occlusion.

Sales 130

Sales 130

Bio Pharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

Sales 293

Sales Drugs Production 293

Bio Pharma Dive

OCTOBER 9, 2023

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Sales 276

Sales Vaccination Vaccine Production 276

Pharma Mirror

JUNE 23, 2023

In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).

Sales 130

Sales Development Marketing 130

Bio Pharma Dive

APRIL 13, 2023

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.

Sales 324

Sales Drugs 324

Pharmaceutical Technology

APRIL 16, 2024

Boehringer Ingelheim announced consistent growth across its human pharma sales and R&D investments in 2023.

Sales 130

Sales 130

Pharmaceutical Technology

MARCH 2, 2023

Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

pharmaphorum

MAY 2, 2024

Sales of Novo Nordisk's obesity drug Wegovy double in Q1, as restrictions on starting doses start to lift in the US.

Sales 109

Sales Drugs 109

Pharmaceutical Technology

JULY 31, 2023

Pharma sales have undergone a seismic transformation after Covid-19, with the adoption of artificial intelligence tools.

Sales 246

Sales 246

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 294

Sales Vaccination Vaccine Production 294

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 317

Sales Development Drugs 317

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.

Sales 246

Sales Engineer Vaccination Vaccine 246

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Sales 305

Sales Gene Therapy Gene Development 305

pharmaphorum

MAY 1, 2024

GSK's recovery gathers pace, with a strong Q1 prompting a rise in sales and earnings forecasts for the full-year.

Sales 104

Sales 104

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales 286

Sales Production Manufacturing 286

Bio Pharma Dive

AUGUST 3, 2023

Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound.

Sales 246

Sales Vaccination Vaccine Production 246

Fierce Pharma

APRIL 2, 2024

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal | Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug (..)

Sales 110

Sales Drugs 110

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 300

Sales Drugs 300

Fierce Pharma

APRIL 26, 2024

AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. | As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis.

Sales 103

Sales 103

Pharmaceutical Technology

AUGUST 23, 2023

Physicians with experience with using AI in their practices were more open to sales representatives using AI to personalise messaging.

Sales 130

Sales 130

Fierce Pharma

APRIL 5, 2024

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S.

Sales 96

Sales Marketing Drugs 96

Bio Pharma Dive

OCTOBER 26, 2023

Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.

Sales 169

Sales Drugs Production 169

Bio Pharma Dive

DECEMBER 5, 2023

The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.

Sales 161

Sales Medicine Drugs 161

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 269

Sales Marketing Vaccination Vaccine 269

Bio Pharma Dive

APRIL 18, 2023

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

Sales 217

Sales Vaccination Vaccine Drugs 217

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

Sales 342

Sales FDA Approval Doctors Doctor 342

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 278

Sales Medicine Drugs Marketing 278

Bio Pharma Dive

OCTOBER 28, 2021

But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 306

Sales Drugs 306

Fierce Pharma

MARCH 20, 2024

Sales came to 1.5 Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1

Sales 133

Sales Vaccination Vaccine 133

Bio Pharma Dive

APRIL 2, 2024

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Sales 294

Sales Marketing Drugs 294

Bio Pharma Dive

MAY 4, 2022

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

Sales 269

Sales Vaccination Vaccine 269

BioSpace

APRIL 23, 2024

Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.

Sales 87

Sales 87

BioSpace

APRIL 23, 2024

Biogen on Wednesday exceeded analyst profit estimates for the first quarter of 2024 as the biotech’s cost-cutting measures took hold and sales of its Alzheimer’s disease therapy Leqembi started to pick up.

Sales 95

Sales 95

Bio Pharma Dive

JULY 21, 2021

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5

Sales 294

Sales Vaccination Vaccine Manufacturing 294

Bio Pharma Dive

FEBRUARY 2, 2023

Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.

Sales 161

Sales Antibody Drugs 161